View Post

Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 Mutations

In Clinical Trials by Barbara Jacoby

By: Rachel Narozniak From: Poziotinib, a novel drug that targets relatively uncommon EGFR and HER2 exon 20 insertion mutations, is being tested in a biomarker-driven trial of patients with non–small cell lung cancer (NSCLC) in both second-line and treatment-naïve settings. The phase II ZENITH20 trial (NCT03318939) is evaluating poziotinib monotherapy, an orally available agent, across 7 cohorts based on …